Martin Stockler
Martin Stockler
Professor of Oncology and Clinical Epidemiology, University of Sydney
Verified email at
Cited by
Cited by
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
IF Tannock, D Osoba, MR Stockler, DS Ernst, AJ Neville, MJ Moore, ...
Journal of clinical oncology 14 (6), 1756-1764, 1996
Bisphosphonates for breast cancer
N Pavlakis, RL Schmidt, MR Stockler
Cochrane Database of Systematic Reviews, 2005
Enzalutamide with standard first-line therapy in metastatic prostate cancer
ID Davis, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, ...
New England Journal of Medicine 381 (2), 121-131, 2019
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III …
NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ...
Journal of clinical oncology 28 (19), 3191-3198, 2010
Single agent versus combination chemotherapy for metastatic breast cancer
S Carrick, S Parker, CE Thornton, D Ghersi, J Simes, N Wilcken
Cochrane Database of Systematic Reviews, 2009
Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
YY Soon, MR Stockler, LM Askie, MJ Boyer
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2009
Bisphosphonates and other bone agents for breast cancer
MHF Wong, MR Stockler, N Pavlakis
Cochrane database of systematic reviews, 2012
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
M Stockler, NRC Wilcken, D Ghersi, RJ Simes
Cancer treatment reviews 26 (3), 151-168, 2000
Third consensus on medical treatment of metastatic breast cancer
S Beslija, J Bonneterre, HJ Burstein, V Cocquyt, M Gnant, V Heinemann, ...
Annals of oncology 20 (11), 1771-1785, 2009
Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials
A Gennari, M Stockler, M Puntoni, M Sormani, O Nanni, D Amadori, ...
Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2011
Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers
KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, S Healey, ...
JNCI: Journal of the National Cancer Institute 109 (7), 2017
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer
MR Stockler, F Hilpert, M Friedlander, MT King, L Wenzel, CK Lee, F Joly, ...
Journal of clinical oncology 32 (13), 1309, 2014
Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer
P Glare, G Pereira, LJ Kristjanson, M Stockler, M Tattersall
Supportive Care in Cancer 12 (6), 432-440, 2004
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 …
GM Duchesne, HH Woo, JK Bassett, SJ Bowe, C D'Este, M Frydenberg, ...
The Lancet Oncology 17 (6), 727-737, 2016
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer
MR Stockler, VJ Harvey, PA Francis, MJ Byrne, SP Ackland, B Fitzharris, ...
J Clin Oncol 29 (34), 4498-4504, 2011
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 …
D Stark, M Nankivell, E Pujade-Lauraine, G Kristensen, L Elit, M Stockler, ...
The lancet oncology 14 (3), 236-243, 2013
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial
MR Stockler, R O'Connell, AK Nowak, D Goldstein, J Turner, ...
The lancet oncology 8 (7), 603-612, 2007
Evidence-based medicine: useful tools for decision making.
JC Craig, LM Irwig, MR Stockler
The Medical Journal of Australia 174 (5), 248-253, 2001
Second consensus on medical treatment of metastatic breast cancer
S Beslija, J Bonneterre, H Burstein, V Cocquyt, M Gnant, P Goodwin, ...
Annals of oncology 18 (2), 215-225, 2007
Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review
CA Hauser, MR Stockler, MHN Tattersall
Supportive Care in Cancer 14 (10), 999-1011, 2006
The system can't perform the operation now. Try again later.
Articles 1–20